Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Simcere Pharmaceutical Group Limited ( (HK:2096) ) has issued an announcement.
Simcere Pharmaceutical Group Limited announced that its anti-tumor drug candidate, SIM0609, a CDH17 Antibody-Drug Conjugate, has received Clinical Trial Approval from China’s National Medical Products Administration. This approval allows the commencement of clinical trials for advanced solid tumors, potentially enhancing Simcere’s position in the oncology market and offering new treatment options for gastrointestinal carcinomas.
More about Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is an innovation and R&D-driven pharmaceutical company focusing on neuroscience, anti-oncology, autoimmune, and anti-infection therapeutic areas. The company has established a ‘State Key Laboratory of Neurology and Oncology Drug Development’ and aims to address significant clinical needs through its strategic partnerships and in-house R&D efforts.
Average Trading Volume: 24,946,085
Technical Sentiment Signal: Buy
Current Market Cap: HK$35.24B
For a thorough assessment of 2096 stock, go to TipRanks’ Stock Analysis page.